The estimated Net Worth of Remy Luthringer is at least 1.45 百万$ dollars as of 28 April 2023. Remy Luthringer owns over 27,394 units of Minerva Neurosciences Inc stock worth over 184,214$ and over the last 10 years he sold NERV stock worth over 105,193$. In addition, he makes 1,164,930$ as Chief Executive Officer and Executive Chairman of the Board of Directors at Minerva Neurosciences Inc.
Remy has made over 4 trades of the Minerva Neurosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 27,394 units of NERV stock worth 105,193$ on 28 April 2023.
The largest trade he's ever made was exercising 34,281 units of Minerva Neurosciences Inc stock on 3 February 2017 worth over 161,464$. On average, Remy trades about 5,220 units every 120 days since 2014. As of 28 April 2023 he still owns at least 68,994 units of Minerva Neurosciences Inc stock.
You can see the complete history of Remy Luthringer stock trades at the bottom of the page.
Dr. Remy Luthringer Ph.D. serves as Chief Executive Officer and Executive Chairman of the Board of Directors of the Company. He has provided services to us since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named our President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on our Board since November 2014. Dr. Luthringer serves as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and previously served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures, and serves on the board of directors of a number of private companies. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur (France). Our Board believes that Dr. Luthringer should serve on our Board due to his extensive knowledge of our business as well as his corporate vision and operational knowledge, which provide strategic guidance to our Board.
As the Chief Executive Officer and Executive Chairman of the Board of Directors of Minerva Neurosciences Inc, the total compensation of Remy Luthringer at Minerva Neurosciences Inc is 1,164,930$. There are 2 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of 2,842,430$.
Remy Luthringer is 59, he's been the Chief Executive Officer and Executive Chairman of the Board of Directors of Minerva Neurosciences Inc since 2018. There are 11 older and 7 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
Remy's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over 49,043,620$ worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth 47,876,311$ . The most active insiders traders include & Johnson Johnson & Johnson...、Venture Associates Iii Ltd ...、Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 556,476$. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth 105,193$.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: